It was never really factored into the current share price but more like a bonus if it advanced to P3. I am not sure if by them stating this they are referring to the partnership aspect that "sanofi" would not be responsible to advance clinical trials and there were still looking to partner it or if its dead completely. If they completely dropped it then I believe zalicus retains ownership of the compound and can advance it themselves.
"Sanofi has decided not to pursue the development of FOV1101 (FDC prednisolone/cyclosporine) in Allergic conjunctivitis." Page 9
CLERIFICATION FROM JUSTIN RENTZ........looks like we are ok
Good morning Ramsay,
"One year ago, Sanofi announced its plans to sublicense its rights to Prednisporin/FOV1101. Sanofi has not advanced its development since that time, and today’s announcement is consistent with last year’s announcement. Zalicus has not been involved in the development of Prednisporin, a legacy asset outlicenced by our predecessor company CombinatoRx in 2006, and does not model revenue from the Sanofi/Prednisporin collaboration in its financial plan or assumptions, as any future revenue would only be accretive to our existing collaboration and royalty revenue. Zalicus will be discussing the future of Prednisporin with Sanofi and will provide an update on the collaboration when there is more information to share.
Thanks for the update Ramsay. Justin is trying to dissociate Zalicus from Prednisporin, but he certainly is not distancing himself from cHTS which is a "legacy" money maker. I look forward to, "Zalicus will be discussing the future of Prednisporin with Sanofi and will provide an update on the collaboration when there is more information to share." Big Red is very much a part of Zalicus, and Dr. Corrigan spoke of Prednisporin at meetings until things turned sour with Sanofi. I look forward to more discussion about this material event and the required SEC filing.
rsc: I remember distinctly that in Sanofi's annual shareholders meeting they said that they were spinning off the ophthalmology group and that Pred and how to proceed with it would be a decision made by the new entity. What happened or what am I missing?